Top Markets
Coin of the day
Instem plc Instem plc

Instem plc

INS
株式のランク #19523
Established in 1969 and based in Stone, United Kingdom, Instem plc provides... Established in 1969 and based in Stone, United Kingdom, Instem plc provides information technology applications to the global life sciences and healthcare sectors. The company's core mission is to equip organizations with robust solutions for data capture, management, and analysis, thereby facilitating informed, data-driven decision-making processes. Instem's extensive suite of offerings addresses diverse needs across research and development. For early-phase clinical trials, it offers ALPHADAS, an eSource system. Discovery research is supported by tools like BioRails for data management and Morphit for data visualization. The portfolio also includes computational toxicology products and services, alongside Provantis, a Windows-based system for non-clinical evaluation studies. Specialized solutions comprise Comet Assay IV, a live video imaging system for reproducible comet slide scoring, and Cyto Study Manager for cytology data acquisition and reporting. Furthermore, NOTOCORD-hem software platforms are available for acquiring, displaying, and analyzing physiological signals. A significant area of focus is regulatory information management. Instem provides Samarind RMS for managing medical product information and a comprehensive set of tools for the Standard for Exchange of Nonclinical Data (SEND). This includes the submit platform for creating and managing SEND datasets, SENDView for reviewing them, SEND Explorer for web-based access with optional data warehousing, and SENDTrial, a subscription-based web solution. Other offerings include Logbook, an information repository, and the Sorcerer Colony Counter for automatic plate counting. Beyond its software products, Instem delivers a broad range of services such as sales support, training, validation, consultancy, and cloud services, in addition to safety assessment and regulatory information management software. The company also develops, manufactures, and supplies both software and hardware specifically for in vitro study data collection and management, enabling intelligence extraction from R&D related healthcare data.
株価
$10.38
最終同期: 2023-11-20
時価総額
$158.81M
変化(1日)
-7.99%
変化(1年)
0.00%
GB
取引 Instem plc (INS)

カテゴリー

Instem plc(INS)のP/E比率
2026 時点のP/E比率 TTM 0
Instem plc の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Instem plc の P/E 比率の履歴(2026 〜 2026)
各年末のP/E比率
P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。